FDA approves its first RNA-based treatment for a rare disease
Contributed by NAMPA / Xinhua.
WASHINGTON, Aug. 10 (Xinhua) -- The United States Food and Drug Administration (FDA) approved on Friday for the first time a new class of drugs called small interfering RNA treatment.
The agency gave a green light to Onpattro infusion for the treatment of peripheral nerve disease caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients, affecting about 50,000 people worldwide.
This is also the first FDA-approved treatment for this rare, debilitating and often fatal gene ...